{"id":28564,"date":"2024-07-29T07:48:13","date_gmt":"2024-07-29T05:48:13","guid":{"rendered":"https:\/\/www.m-q.ch\/?p=20148"},"modified":"2024-11-09T10:36:01","modified_gmt":"2024-11-09T09:36:01","slug":"amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick","status":"publish","type":"post","link":"https:\/\/www.organisator.ch\/it\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","title":{"rendered":"Amporin Pharmaceuticals riceve 150.000 franchi da Venture Kick"},"content":{"rendered":"<figure id=\"attachment_20150\" class=\"wp-caption alignnone\" style=\"width: 680px\" aria-describedby=\"caption-attachment-20150\"><img class=\"alignnone wp-image-20150 size-full\" src=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" alt=\"Amporin Pharma Innovazione 2024\" width=\"680\" height=\"392\" \/>\r\n<figcaption id=\"caption-attachment-20150\" class=\"wp-caption-text\">I co-fondatori di Amporin: il CSO Dr Herv\u00e9 Schaffhauser, il CEO Dr Kelvin Stott e il CMO Prof Daniel Umbricht. (Immagine: www.venturekick.ch)<\/figcaption>\r\n<\/figure>\r\n<p>Oltre 50 malattie degenerative mortali, tra cui il morbo di Alzheimer, il Parkinson, il diabete di tipo II e molte malattie neurodegenerative rare, sono legate al misfolding e all'aggregazione delle proteine. Queste malattie colpiscono pi\u00f9 di mezzo miliardo di persone in tutto il mondo e causano 3,6 milioni di vittime ogni anno, con un costo per la societ\u00e0 di circa 3 miliardi di dollari all'anno. Ad oggi, non esistono trattamenti efficaci in grado di arrestare o invertire la progressiva degenerazione.\u00a0<\/p>\r\n<p>Amporin Pharmaceuticals mira a sviluppare una nuova classe di farmaci a piccole molecole che bloccano ed eliminano gli oligomeri solubili e i pori tossici nelle membrane cellulari. Queste sostanze tossiche si accumulano e distruggono le cellule creando buchi nelle membrane cellulari, portando alla perdita dell'omeostasi e alla progressiva degenerazione. L'azienda intende sviluppare e commercializzare i primi trattamenti orali modificanti la malattia efficaci e acuti per un massimo di sei malattie principali, tra cui il morbo di Alzheimer e il diabete di tipo II, con un'attenzione iniziale al morbo di Parkinson e alla SLA (sclerosi laterale amiotrofica).<\/p>\r\n<p>La sola malattia di Parkinson colpisce circa un milione di persone negli Stati Uniti e circa dieci milioni di persone nel mondo. L'attuale mercato globale dei farmaci per la malattia di Parkinson \u00e8 di circa 6 miliardi di dollari all'anno, con un mercato potenziale di 15 miliardi di dollari all'anno per i primi trattamenti efficaci che modificano la malattia.<\/p>\r\n<p>I 150.000 franchi di Venture Kick consentiranno all'azienda di stabilire le sue attivit\u00e0 principali e di creare un pacchetto completo di dati in vitro per convalidare e dimostrare i vantaggi unici della sua tecnologia a potenziali investitori e partner di licenza.<\/p>\r\n<p>Il team fondatore di Amporin comprende il CEO Dr. Kelvin Stott, il CSO Dr. Herv\u00e9 Schaffhauser e il CMO Prof. Daniel Umbricht, ognuno dei quali vanta oltre 20 anni di esperienza nello sviluppo di farmaci per il sistema nervoso centrale e nella conduzione di attivit\u00e0 di ricerca e sviluppo in diverse grandi aziende farmaceutiche e start-up biotecnologiche.<\/p>\r\n<p>\"Venture Kick \u00e8 stato fondamentale per aiutarci a costruire un'azienda di livello mondiale con una tecnologia che ha cambiato il mondo\", sottolinea Kelvin Stott, cofondatore e CEO di Amporin Pharmaceuticals. \"Senza Venture Kick, non avremmo avuto l'opportunit\u00e0 di realizzare il nostro potenziale\".<\/p>\r\n<p><em>Fonte: <a href=\"http:\/\/www.venturekick.ch\/\">www.venturekick.ch<\/a><\/em><\/p>\n<p class=\"syndicated-attribution\">Questo articolo \u00e8 apparso originariamente su m-q.ch - <a href=\"https:\/\/www.m-q.ch\/de\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\" target=\"_blank\">https:\/\/www.m-q.ch\/de\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Amporin Pharmaceuticals ha ricevuto un investimento di 150.000 franchi svizzeri da Venture Kick per promuovere lo sviluppo di inibitori dei pori amiloidi per il trattamento di malattie degenerative fatali.<\/p>","protected":false},"author":58,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_yoast_wpseo_focuskw":"Amporin Pharma Innovation 2024","_yoast_wpseo_metadesc":"Amporin entwickelt Medikamente gegen degenerative Krankheiten wie Alzheimer und Parkinson. Venture Kick unterst\u00fctzt mit CHF 150'000.","articlekey":"","footnotes":""},"categories":[582],"tags":[1441,605,492,3934],"class_list":["post-28564","post","type-post","status-publish","format-standard","hentry","category-operational-excellence","tag-investition","tag-qualitaetsmanagement","tag-unternehmen","tag-venture-kick"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick - Organisator<\/title>\n<meta name=\"description\" content=\"Amporin entwickelt Medikamente gegen degenerative Krankheiten wie Alzheimer und Parkinson. Venture Kick unterst\u00fctzt mit CHF 150&#039;000.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.organisator.ch\/it\/eccellenza-operativa\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick - Organisator\" \/>\n<meta property=\"og:description\" content=\"Amporin entwickelt Medikamente gegen degenerative Krankheiten wie Alzheimer und Parkinson. Venture Kick unterst\u00fctzt mit CHF 150&#039;000.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.organisator.ch\/it\/eccellenza-operativa\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\" \/>\n<meta property=\"og:site_name\" content=\"Organisator\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/OrganisatorFachmagazin\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-29T05:48:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-09T09:36:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n<meta name=\"author\" content=\"Adelisa Kalajdzini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/\"},\"author\":{\"name\":\"Adelisa Kalajdzini\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#\\\/schema\\\/person\\\/2e1314a2172123f874db408d8911d3f3\"},\"headline\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"dateModified\":\"2024-11-09T09:36:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/\"},\"wordCount\":366,\"publisher\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m-q.ch\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Amporin_Bild1_ps.jpg\",\"keywords\":[\"Investition\",\"Qualit\u00e4tsmanagement\",\"Unternehmen\",\"Venture Kick\"],\"articleSection\":[\"OPERATIONAL EXCELLENCE\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/\",\"url\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/\",\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick - Organisator\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m-q.ch\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Amporin_Bild1_ps.jpg\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"dateModified\":\"2024-11-09T09:36:01+00:00\",\"description\":\"Amporin entwickelt Medikamente gegen degenerative Krankheiten wie Alzheimer und Parkinson. Venture Kick unterst\u00fctzt mit CHF 150'000.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.m-q.ch\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Amporin_Bild1_ps.jpg\",\"contentUrl\":\"https:\\\/\\\/www.m-q.ch\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Amporin_Bild1_ps.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/operational-excellence\\\/2024-07-29\\\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.organisator.ch\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#website\",\"url\":\"https:\\\/\\\/www.organisator.ch\\\/\",\"name\":\"Organisator\",\"description\":\"Kompetent. Praxisnah. Der ORGANISATOR bereitet in 10 Ausgaben pro Jahr die wesentlichen Themen f\u00fcr F\u00fchrungskr\u00e4fte von KMU auf.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.organisator.ch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#organization\",\"name\":\"Organisator\",\"url\":\"https:\\\/\\\/www.organisator.ch\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.organisator.ch\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/Logo_Organisator_Website.png\",\"contentUrl\":\"https:\\\/\\\/www.organisator.ch\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/Logo_Organisator_Website.png\",\"width\":800,\"height\":77,\"caption\":\"Organisator\"},\"image\":{\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/OrganisatorFachmagazin\",\"https:\\\/\\\/www.linkedin.com\\\/showcase\\\/organisator-das-magazin-fr-kmu\",\"https:\\\/\\\/www.xing.com\\\/news\\\/pages\\\/organisator-ch-695\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCGP2Sq0iWaZwT3BdIAQFYpw\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.organisator.ch\\\/#\\\/schema\\\/person\\\/2e1314a2172123f874db408d8911d3f3\",\"name\":\"Adelisa Kalajdzini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g\",\"caption\":\"Adelisa Kalajdzini\"},\"url\":\"https:\\\/\\\/www.organisator.ch\\\/it\\\/author\\\/adelisa-kalajdzini\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amporin Pharmaceuticals riceve 150.000 franchi da Venture Kick - Organizzatore","description":"Amporin sviluppa farmaci contro malattie degenerative come l'Alzheimer e il Parkinson. Venture Kick sostiene la societ\u00e0 con 150.000 franchi svizzeri.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.organisator.ch\/it\/eccellenza-operativa\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","og_locale":"it_IT","og_type":"article","og_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick - Organisator","og_description":"Amporin entwickelt Medikamente gegen degenerative Krankheiten wie Alzheimer und Parkinson. Venture Kick unterst\u00fctzt mit CHF 150'000.","og_url":"https:\/\/www.organisator.ch\/it\/eccellenza-operativa\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","og_site_name":"Organisator","article_publisher":"https:\/\/www.facebook.com\/OrganisatorFachmagazin","article_published_time":"2024-07-29T05:48:13+00:00","article_modified_time":"2024-11-09T09:36:01+00:00","og_image":[{"url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","type":"","width":"","height":""}],"author":"Adelisa Kalajdzini","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article","isPartOf":{"@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"author":{"name":"Adelisa Kalajdzini","@id":"https:\/\/www.organisator.ch\/#\/schema\/person\/2e1314a2172123f874db408d8911d3f3"},"headline":"Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick","datePublished":"2024-07-29T05:48:13+00:00","dateModified":"2024-11-09T09:36:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"wordCount":366,"publisher":{"@id":"https:\/\/www.organisator.ch\/#organization"},"image":{"@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","keywords":["Investition","Qualit\u00e4tsmanagement","Unternehmen","Venture Kick"],"articleSection":["OPERATIONAL EXCELLENCE"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","url":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","name":"Amporin Pharmaceuticals riceve 150.000 franchi da Venture Kick - Organizzatore","isPartOf":{"@id":"https:\/\/www.organisator.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"image":{"@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","datePublished":"2024-07-29T05:48:13+00:00","dateModified":"2024-11-09T09:36:01+00:00","description":"Amporin sviluppa farmaci contro malattie degenerative come l'Alzheimer e il Parkinson. Venture Kick sostiene la societ\u00e0 con 150.000 franchi svizzeri.","breadcrumb":{"@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.organisator.ch\/operational-excellence\/2024-07-29\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.organisator.ch\/"},{"@type":"ListItem","position":2,"name":"Amporin Pharmaceuticals erh\u00e4lt CHF 150\u2019000 von Venture Kick"}]},{"@type":"WebSite","@id":"https:\/\/www.organisator.ch\/#website","url":"https:\/\/www.organisator.ch\/","name":"Organizzatore","description":"Competente. Pratico. In 10 numeri all'anno, ORGANISATOR presenta i temi essenziali per i manager delle PMI.","publisher":{"@id":"https:\/\/www.organisator.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.organisator.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.organisator.ch\/#organization","name":"Organizzatore","url":"https:\/\/www.organisator.ch\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.organisator.ch\/#\/schema\/logo\/image\/","url":"https:\/\/www.organisator.ch\/wp-content\/uploads\/2022\/01\/Logo_Organisator_Website.png","contentUrl":"https:\/\/www.organisator.ch\/wp-content\/uploads\/2022\/01\/Logo_Organisator_Website.png","width":800,"height":77,"caption":"Organisator"},"image":{"@id":"https:\/\/www.organisator.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/OrganisatorFachmagazin","https:\/\/www.linkedin.com\/showcase\/organisator-das-magazin-fr-kmu","https:\/\/www.xing.com\/news\/pages\/organisator-ch-695","https:\/\/www.youtube.com\/channel\/UCGP2Sq0iWaZwT3BdIAQFYpw"]},{"@type":"Person","@id":"https:\/\/www.organisator.ch\/#\/schema\/person\/2e1314a2172123f874db408d8911d3f3","name":"Adelisa Kalajdzini","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g","caption":"Adelisa Kalajdzini"},"url":"https:\/\/www.organisator.ch\/it\/author\/adelisa-kalajdzini\/"}]}},"_links":{"self":[{"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/posts\/28564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/users\/58"}],"replies":[{"embeddable":true,"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/comments?post=28564"}],"version-history":[{"count":6,"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/posts\/28564\/revisions"}],"predecessor-version":[{"id":32108,"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/posts\/28564\/revisions\/32108"}],"wp:attachment":[{"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/media?parent=28564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/categories?post=28564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.organisator.ch\/it\/wp-json\/wp\/v2\/tags?post=28564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}